neratinib

01/01/2021 - "Neratinib has great efficacy in treating HER2+ breast cancer but is associated with significant gastrointestinal toxicity. "
10/09/2018 - "Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)."
01/01/2020 - "Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial."
10/10/2019 - "Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10."
10/06/2023 - "This article reviewed the pharmacological profiles, efficacy, safety, tolerability, and current clinical trials pertaining to neratinib, with a particular focus on the use of neratinib in patients with metastatic breast cancer (MBC) involving the CNS. "

01/01/2019 - "In vivo, using mouse cancer models, neratinib significantly enhanced the antitumor efficacy of [regorafenib + sildenafil]. "
10/01/2014 - "Neratinib treated mice harboring xenografts of HER2/neu amplified USC showed delayed tumor growth and improved overall survival compared to vehicle (p=0.0019). "
01/01/2015 - "Neratinib has been shown to be effective against HER2-overexpressing or mutant tumors in vitro and in vivo. "
01/01/2021 - "In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of downstream signaling in HER2+ cancers in vitro and in vivo. "
01/01/2022 - "Simulations are based on the original design of a real-world clinical trial, the SUMMIT trial, which investigated Neratinib treatment for a variety of solid tumors. "

11/01/2020 - "Neratinib, has shown that it was able to delay brain metastases progression. "
12/01/2016 - "Neratinib in ERBB2-Positive Brain Metastases."
03/20/2016 - "We evaluated the efficacy of treatment with neratinib in patients with HER2-positive breast cancer brain metastases in a multicenter, phase II open-label trial. "
01/01/2021 - "Neratinib in HER2-Positive Breast Cancer With Brain Metastases."
01/01/2020 - "Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022."

05/01/2017 - "The objective of our study was to evaluate neratinib's preclinical efficacy in treating HER2-amplified ovarian cancer. "
05/01/2017 - "Neratinib's efficacy in treating HER2-amplified ovarian cancer was studied in vitro utilizing six primary tumor cell lines with differential HER2/neu expression. "
12/01/2019 - "Clinical investigations of neratinib in ErbB2-positive ovarian cancer are warranted."
12/01/2019 - "Therefore, the ubiquitylation-mediated endocytic degradation of ErbB2 incurred by neratinib treatment conferred potent inhibition of ovarian cancer growth. "
12/01/2019 - "Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer."

01/01/2020 - "Neratinib tolerability was improved with preemptive prophylaxis or DE, which reduced the rate, severity, and duration of neratinib-associated grade ≥3 diarrhea compared with ExteNET. "
01/01/2021 - "Our machine learning model identified microbiota associated with reduced risk of neratinib-induced diarrhea and the result from this pilot study will be further verified in a larger study. "
01/01/2021 - "In this study, we developed a reproducible model for neratinib-induced diarrhea in male and female rats. "
01/01/2020 - "Neratinib resulted in expected rates of diarrhea in this small cohort, with 2 of 5 patients receiving the study treatment for durable periods. "
07/01/2012 - "The objective of this study was to characterize the onset, severity, and duration of diarrhea after administration of neratinib 240 mg once daily (QD) and 120 mg twice daily (BID) for ≤14 days in healthy subjects. "